fluprednisolone has been researched along with Scleritis in 2 studies
Fluprednisolone: A synthetic glucocorticoid with anti-inflammatory properties.
Scleritis: Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data collected from all patients with anterior scleritis who used difluprednate as a single treatment agent from January 1, 2018, to January 1, 2020, including demographics, scleritis type, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, best-corrected visual acuity (BCVA), and lens status." | 8.12 | Effectiveness of Difluprednate for the Treatment of Anterior Scleritis. ( Berkenstock, MK; Burkholder, BM; Liberman, P; Thorne, JE, 2022) |
| "Data collected from all patients with anterior scleritis who used difluprednate as a single treatment agent from January 1, 2018, to January 1, 2020, including demographics, scleritis type, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, best-corrected visual acuity (BCVA), and lens status." | 4.12 | Effectiveness of Difluprednate for the Treatment of Anterior Scleritis. ( Berkenstock, MK; Burkholder, BM; Liberman, P; Thorne, JE, 2022) |
| "Difluprednate 0." | 1.36 | Intraocular pressure elevation from topical difluprednate use. ( Meehan, K; Sowka, J; Vollmer, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liberman, P | 1 |
| Burkholder, BM | 1 |
| Thorne, JE | 1 |
| Berkenstock, MK | 1 |
| Meehan, K | 1 |
| Vollmer, L | 1 |
| Sowka, J | 1 |
2 other studies available for fluprednisolone and Scleritis
| Article | Year |
|---|---|
Effectiveness of Difluprednate for the Treatment of Anterior Scleritis.
Topics: Adolescent; Adult; Aged; Female; Fluprednisolone; Glucocorticoids; Humans; Intraocular Pressure; Mid | 2022 |
Intraocular pressure elevation from topical difluprednate use.
Topics: Administration, Topical; Black or African American; Emulsions; Female; Fluprednisolone; Glucocortico | 2010 |